Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma

Abstract Bronchial asthma is the most frequently diagnosed chronic respiratory disease in children. Treatment approaches should aim to achieve control, reduce limiting symptoms, and improve quality of life. Routine treatment patients with relies on assessment symptoms spirometry results. These diagnostic therapeutic strategies do not consider level inflammation airways as a fundamental pathognomonic feature disease. The use biomarkers increasing context efforts better understand individual pathways (asthma endotyping), potential for personalized innovative biologics. Elevated levels exhaled nitric oxide (FENO) represent an indirect marker T2 airways. FENO one few that have been applied routine clinical practice. High predict good response corticosteroids selected biologics (Omalizumab, Dupilumab, Mepolizumab, Tezepelumab), or increased risk exacerbation. this review evaluate advantages, disadvantages, applications test relation new options using asthma.